This is week three of this season of The Bachelor on ABC, and week three of a patient-related subject highlighted on the show (Colton's CF foundation, Caelynn's childhood encephalitis)-- so I'm…
Joe Marksteiner, a 22-year Air Force veteran and former gymnast, won a title at the 2013 World Powerlifting Championships at the age of 60. This year, now at 65, he…
Over 55,000 people are diagnosed with pancreatic cancer every year. And about 95 percent of people who are diagnosed with pancreatic cancer will lose their lives from it. Pancreatic…
According to a story from globenewswire.com, the company Progenic Pharmaceuticals recently reported the the U.S. Food and Drug Administration has recently approved the company's product iobenguane I 131 (AZEDRA). This…
According to a story from bioengineer.org, a group of scientists working at the Columbia University Irving Medical Center (CUIMC) have managed to develop a computational model that could potentially make highly…
According to a story from news-medical.net, the results of a recent research trial demonstrate that the radiation therapy drug AZEDRA (ultratrace iobenguane I131) is an effective and safe treatment option…
In a press release, CURE Media Group announced the development of a 13-part series on carcinoid syndrome. A series of discussions involving both doctors and patients educating patients, caregivers and…
According to a story from biospace.com, a research team from the National Cancer Institute was able to successfully deliver an experimental nanomedicine to mice that had rare cancers such as…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
